These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
389 related articles for article (PubMed ID: 20924413)
1. ANCA-associated vasculitides--advances in pathogenesis and treatment. Chen M; Kallenberg CG Nat Rev Rheumatol; 2010 Nov; 6(11):653-64. PubMed ID: 20924413 [TBL] [Abstract][Full Text] [Related]
2. Updates in ANCA-associated vasculitis. Ross C; Makhzoum JP; Pagnoux C Eur J Rheumatol; 2022 Jul; 9(3):153-166. PubMed ID: 35156630 [TBL] [Abstract][Full Text] [Related]
3. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach. Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313 [TBL] [Abstract][Full Text] [Related]
4. ANCA-Associated Vasculitis: Core Curriculum 2020. Geetha D; Jefferson JA Am J Kidney Dis; 2020 Jan; 75(1):124-137. PubMed ID: 31358311 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA; Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823 [TBL] [Abstract][Full Text] [Related]
6. The role of rituximab in the treatment of ANCA-associated vasculitides (AAV). Daikeler T; Kistler AD; Martin PY; Vogt B; Huynh-Do U Swiss Med Wkly; 2015; 145():w14103. PubMed ID: 25658140 [TBL] [Abstract][Full Text] [Related]
16. Updates in ANCA-associated vasculitis. Pagnoux C Eur J Rheumatol; 2016 Sep; 3(3):122-133. PubMed ID: 27733943 [TBL] [Abstract][Full Text] [Related]
17. L52. Vasculitis treatment: is it time to change the standard of care for ANCA-associated vasculitis? Hoffman GS Presse Med; 2013 Apr; 42(4 Pt 2):643-50. PubMed ID: 23474045 [No Abstract] [Full Text] [Related]
18. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC; J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429 [TBL] [Abstract][Full Text] [Related]
19. S1. Rituximab for ANCA-associated vasculitis: the experience in the United States. Clain JM; Specks U Presse Med; 2013 Apr; 42(4 Pt 2):530-2. PubMed ID: 23477713 [No Abstract] [Full Text] [Related]
20. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Ding L; Iklé D; Villareal M; Lim N; Brunetta P; Fervenza FC; Monach PA; Stone JH; Arthritis Rheumatol; 2015 Jun; 67(6):1629-36. PubMed ID: 25776953 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]